From the Journals

Study supports multigene panel testing for all breast cancer patients with second primary cancers


 

FROM JCO PRECISION ONCOLOGY

Cancer prevention and screening

The results of this study could lead to better implementation of cancer prevention and screening strategies, according to the researchers.

“As we look at guidelines in development and NCCN recommendations, our data suggest that age should not be part of the criteria for genetic testing in patients who have more than one primary cancer. These patients are at high risk and should be recommended for screening,” Dr. Nathanson said.

“If you see a patient with multiple primary cancers, refer for genetic testing. Age does not matter,” she reiterated.

Future research will look at potentially missing mutations.

“With targeted sequencing, structurally rearranged genes might be missed for those at risk. We will try to identify cancer susceptibility genes and define the true risk of penetrance of these genes in the general population,” Dr. Nathanson said.

This research was supported by grants from government agencies and foundations as well as the University of Pennsylvania. Dr. Nathanson disclosed no conflicts of interest. Other authors disclosed relationships with a range of companies, all listed in the paper.

SOURCE: Maxwell KN et al. JCO Precis Oncol. 2020. doi: 10.1200/PO.19.00301.

Pages

Recommended Reading

Tailored messaging needed to get cancer screening back on track
Breast Cancer ICYMI
One-off blast of RT, rather than weeks, for early breast cancer
Breast Cancer ICYMI
Aspirin may accelerate cancer progression in older adults
Breast Cancer ICYMI
Immunotherapy should not be withheld because of sex, age, or PS
Breast Cancer ICYMI
First guideline on NGS testing in cancer, from ESMO
Breast Cancer ICYMI
VTE, sepsis risk increased among COVID-19 patients with cancer
Breast Cancer ICYMI
A Rare Case of Triple Positive Inflammatory Breast Cancer in An Elderly Male
Breast Cancer ICYMI
Chronicles of Cancer: A history of mammography, part 2
Breast Cancer ICYMI
Hair dye and cancer study ‘offers some reassurance’
Breast Cancer ICYMI
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results
Breast Cancer ICYMI